Singapore Institute of Advance (9G2) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Singapore Institute of Advance stock S$0.03, price S$0.03, that is 1.0% below the price, quality 27 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Singapore Institute of Advance
9G2 · SGThe stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
33‑month range 0.0200 SGD – 0.1900 SGD · fair‑value band 0.0250 SGD – 0.0285 SGD · the 0.0270 SGD price screens above the 0.0267 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Singapore Institute of Advance is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Singapore Institute of Advanced Medicine Holdings Ltd., an investment holding company, provides medical diagnostics and treatments, and radiation therapy and medical oncology services in Singapore.
Show moreShow less
The company offers medical diagnostics and treatments, including cancer-related diagnostics and theragnostic treatments, general diagnostics and health screening, and aesthetic services; and radiation therapy and medical oncology services comprise proton beam therapy, photon radiation therapy, and medical oncology services.
It provides clinic and imaging services; manufactures medical research and clinical diagnostic instruments and supplies; and sells pharmaceuticals, surgical products, and consumables. Singapore Institute of Advanced Medicine Holdings Ltd. was incorporated in 2011 and is based in Singapore.
Stock analysis
Singapore Institute of Advance (9G2) currently trades at 0.0270 SGD, while our estimate is 0.0267 SGD, so the stock looks roughly fairly valued today (gap 1.0%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 0.0250 SGD (bear) to 0.0285 SGD (bull), the price of 0.0270 SGD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Singapore Institute of Advance reported revenue of 15.7M SGD in FY2026 versus 13.8M SGD in FY2022, a compound +3.3%/yr. Reported net income was −23.9M SGD in FY2026.
Key figures
Market cap 46.6M SGD (≈ $36.1M) Micro · P/S ratio 2.19 · EPS (TTM) −0.0200 SGD · Return on equity −44.0% · Return on assets (EBIT) −12.9% (5-year average) · Operating margin −152% · Revenue (TTM) 15.7M SGD · Revenue growth (YoY) −11.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 66% below its 52-week high and 35% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −1%, 9G2 screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch 9G2, get fair value alerts →
Compare Singapore Institute of Advance with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Healthcare
- Valuation of the Singapore market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Fresenius Medical Care AG FMS | $22.03 | $45.73 | +108% | vs 9G2 |
| DaVita Inc DVA | $174.56 | $218.90 | +25% | vs 9G2 |
| Aier Eye Hospital Group 300015 | ¥8.99 | ¥10.88 | +21% | vs 9G2 |
| HCA Healthcare, Inc HCA | $499.05 | $547.34 | +10% | vs 9G2 |
| Tenet Healthcare Corporation THC | $286.03 | $279.20 | −2% | vs 9G2 |
| The Ensign Group ENSG | $188.41 | $140.09 | −26% | vs 9G2 |
| Encompass Health Corporation EHC | $140.99 | $94.81 | −33% | vs 9G2 |
| Fresenius SE FRE | €53.86 | €34.77 | −35% | vs 9G2 |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,771 | ₹5,234 | −40% | vs 9G2 |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 211.40 SAR | 109.45 SAR | −48% | vs 9G2 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Singapore Institute of Advance (9G2) overvalued or undervalued?
What is the fair value of 9G2?
What is the quality score of 9G2?
What is the price target for Singapore Institute of Advance (9G2)?
What is the Singapore Institute of Advance stock forecast for 2026?
What is the revenue of Singapore Institute of Advance (9G2)?
What is the intrinsic value of Singapore Institute of Advance (9G2)?
Is Singapore Institute of Advance stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 9G2?
How much is Singapore Institute of Advance worth?
What do the bullish and bearish scenarios say about 9G2?
How solid is the balance sheet of Singapore Institute of Advance (9G2)?
How far is 9G2 from its 52-week high?
Which stocks are comparable to Singapore Institute of Advance?
Is Singapore Institute of Advance stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Singapore Institute of Advance (9G2)?
What should I pay attention to with Singapore Institute of Advance right now?
Key figures of Singapore Institute of Advance
How large is the market capitalisation of Singapore Institute of Advance (9G2)?
What is the P/S ratio of Singapore Institute of Advance (9G2)?
What are the earnings per share of Singapore Institute of Advance (9G2)?
What is the return on equity of Singapore Institute of Advance (9G2)?
What is the EBIT return on assets of Singapore Institute of Advance (9G2)?
What is the operating margin of Singapore Institute of Advance (9G2)?
How fast is revenue growing at Singapore Institute of Advance (9G2)?
How much free cash flow does Singapore Institute of Advance (9G2) generate?
How much net debt does Singapore Institute of Advance (9G2) carry?
Watch Singapore Institute of Advance in the live analysis
One click puts Singapore Institute of Advance on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.